A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Pramipexole Dihydrochloride

Nonergot Dopamine Agonist class · 16 generic manufacturers · 94 ANDAs filed at FDA.

First FDA approval2010-10-08
Generic availableYes · 16 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.041/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.047
Across all dosage forms in distribution.
Highest NADAC
$0.056
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Pramipexole Dihydrochloride used for?

Pramipexole Dihydrochloride is a Nonergot Dopamine Agonist medication tracked in Medicare Part D.

Is there a generic for Pramipexole Dihydrochloride?

Yes. 94 ANDAs filed at FDA, 16 generic manufacturers currently shipping.

How much does my plan pay for Pramipexole Dihydrochloride?

Across 329 Part D plans, Pramipexole Dihydrochloride averages $0.047/unit (NADAC). Lowest available: $0.041/unit. Highest in distribution: $0.056/unit.

Is Pramipexole Dihydrochloride on the FDA shortage list?

No. Pramipexole Dihydrochloride is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Nonergot Dopamine Agonist2 alternatives in D1
01
Ropinirole
Nonergot Dopamine Agonist
$0.043Lowest NADAC
13Generic mfrs
$97.6MCY24 Part D spend
Compare →
02
Rotigotine
Brand: Neupro
$28.21Lowest NADAC
0Generic mfrs
$128.5MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.